UCFA
BMRN icon

United Capital Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

United Capital Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,995
Closed -$263K – 1069
2024
Q4 		$263K Buy
+3,995
New +$268K ﹤0.01% 930
2024
Q3 		– Sell
-4,742
Closed -$390K – 1067
2024
Q2 		$390K Sell
4,742
-1,408
-23% -$117K ﹤0.01% 777
2024
Q1 		$537K Buy
6,150
+3,250
+112% +$291K ﹤0.01% 722
2023
Q4 		$280K Buy
2,900
+216
+8% +$19.1K ﹤0.01% 897
2023
Q3 		$237K Buy
2,684
+28
+1% +$2.49K ﹤0.01% 767
2023
Q2 		$230K Sell
2,656
-303
-10% -$28.5K ﹤0.01% 825
2023
Q1 		$288K Sell
2,959
-2,026
-41% -$210K ﹤0.01% 837
2022
Q4 		$516K Sell
4,985
-9,208
-65% -$864K ﹤0.01% 748
2022
Q3 		$1.2M Sell
14,193
-42
-0.3% -$3.74K 0.01% 576
2022
Q2 		$1.18M Sell
14,235
-375
-3% -$29.9K 0.01% 604
2022
Q1 		$1.13M Sell
14,610
-240
-2% -$20.1K 0.01% 638
2021
Q4 		$1.31M Sell
14,850
-420
-3% -$34.7K 0.01% 624
2021
Q3 		$1.18M Buy
15,270
+95
+0.6% +$7.5K 0.01% 632
2021
Q2 		$1.27M Sell
15,175
-8,483
-36% -$672K 0.01% 639
2021
Q1 		$1.79M Buy
23,658
+14,391
+155% +$1.18M 0.01% 529
2020
Q4 		$813K Sell
9,267
-8,899
-49% -$706K ﹤0.01% 731
2020
Q3 		$1.38M Buy
18,166
+12,733
+234% +$1.29M 0.01% 583
2020
Q2 		$670K Buy
5,433
+240
+5% +$23.9K ﹤0.01% 767
2020
Q1 		$439K Buy
5,193
+1,447
+39% +$125K ﹤0.01% 859
2019
Q4 		$317K Buy
+3,746
New +$283K ﹤0.01% 1122

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

United Capital Financial Advisors's BMRN Position: Q1 2025 in Review

United Capital Financial Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 3,995 shares — an estimated $263K sold.

United Capital Financial Advisors first reported a position in BMRN in Q4 2019 and held it in 20 quarters. The position peaked at $1.79M in Q1 2021. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • United Capital Financial Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • United Capital Financial Advisors sold 3,995 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $263K.
  • United Capital Financial Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 20 quarters.
  • United Capital Financial Advisors's BioMarin Pharmaceuticals position peaked at $1.79M in Q1 2021.
  • 584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on United Capital Financial Advisors's 13F filing for Q1 2025, filed 13 May 2025.